Correlation of airway obstruction and patient-reported endpoints in clinical studies

被引:74
作者
Shingo, S
Zhang, J
Reiss, TF
机构
[1] Merck Res Labs, Dept Clin Biostat, Rahway, NJ 07065 USA
[2] Merck Res Labs, Dept Pulm & Immunol, Rahway, NJ 07065 USA
关键词
as-needed beta-agonist use; asthma; correlation; FEV1; PEF; symptom;
D O I
10.1183/09031936.01.17202200
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
To establish the correlation among asthma efficacy parameters over a long period, data from over 1500 patients in two one-year asthma clinical trials with montelukast, a Cys-LT1 antagonist,were analysed. Airway obstruction measurements, forced expiratory volume: in one second (FEV1) and peak expiratory flow (PEF), were measured at clinic visits. Patients recorded daytime symptom score, "as-needed" beta -agonist use, and PEF on a daily basis. Relationships among these parameters at baseline and during the one-year treatment period were established by correlation analyses. Multiple correlations between the airway obstruction (FEV1 and PEF) and patient-reported measurements were evaluated by canonical correlation analysis, Pairwise correlations of the efficacy parameters over a one-year time period were stable, Canonical correlation between the airway obstruction and patient-reported asthma efficacy endpoints mas low, indicating that each category of endpoints measures a distinctively different aspect of the disease. It appears that at least one endpoint from each category should be used in asthma clinical studies.
引用
收藏
页码:220 / 224
页数:5
相关论文
共 12 条
[2]   Perception of airway obstruction in asthma: Sequential daily analyses of symptoms, peak expiratory flow rate, and mood [J].
Apter, AJ ;
Affleck, G ;
Reisine, ST ;
Tennen, HA ;
Barrows, E ;
Wells, M ;
Willard, A ;
ZuWallack, RL .
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 1997, 99 (05) :605-612
[3]   COMMON MEASURES OF ASTHMA SEVERITY LACK ASSOCIATION FOR DESCRIBING ITS CLINICAL COURSE [J].
APTER, AJ ;
ZUWALLACK, RL ;
CLIVE, J .
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 1994, 94 (04) :732-737
[4]   THE MOOD PEAK FLOW RELATIONSHIP IN ADULT ASTHMATICS - A PILOT-STUDY OF INDIVIDUAL-DIFFERENCES AND DIRECTION OF CAUSALITY [J].
HYLAND, ME .
BRITISH JOURNAL OF MEDICAL PSYCHOLOGY, 1990, 63 :379-384
[5]   EVALUATION OF IMPAIRMENT OF HEALTH RELATED QUALITY-OF-LIFE IN ASTHMA - DEVELOPMENT OF A QUESTIONNAIRE FOR USE IN CLINICAL-TRIALS [J].
JUNIPER, EF ;
GUYATT, GH ;
EPSTEIN, RS ;
FERRIE, PJ ;
JAESCHKE, R ;
HILLER, TK .
THORAX, 1992, 47 (02) :76-83
[6]   Oral montelukast, inhaled beclomethasone, and placebo for chronic asthma -: A randomized, controlled trial [J].
Malmstrom, K ;
Rodriguez-Gomez, G ;
Guerra, J ;
Villaran, C ;
Piñeiro, A ;
Wei, LX ;
Seidenberg, BC ;
Reiss, TF .
ANNALS OF INTERNAL MEDICINE, 1999, 130 (06) :487-+
[7]  
MALMSTROM K, 1996, EUR RESPIR J, V9, pS273
[8]  
*NIH, 1995, PUBL NIH, V95, P813
[9]   Montelukast, a once-daily leukotriene receptor antagonist, in the treatment of chronic asthma -: A multicenter, randomized, double-blind trial [J].
Reiss, TF ;
Chervinsky, P ;
Dockhorn, RJ ;
Shingo, S ;
Seidenberg, B ;
Edwards, TB .
ARCHIVES OF INTERNAL MEDICINE, 1998, 158 (11) :1213-1220
[10]  
Santanello NC, 1997, EUR RESPIR J, V10, P646